MX350731B - Procesos para la preparacion de (s)-1-(3-etoxi-4-metoxifenil)-2-me tansulfoniletilamina. - Google Patents

Procesos para la preparacion de (s)-1-(3-etoxi-4-metoxifenil)-2-me tansulfoniletilamina.

Info

Publication number
MX350731B
MX350731B MX2016016157A MX2016016157A MX350731B MX 350731 B MX350731 B MX 350731B MX 2016016157 A MX2016016157 A MX 2016016157A MX 2016016157 A MX2016016157 A MX 2016016157A MX 350731 B MX350731 B MX 350731B
Authority
MX
Mexico
Prior art keywords
ethoxy
processes
preparation
methanesulfonylethylamine
methoxyphenyl
Prior art date
Application number
MX2016016157A
Other languages
English (en)
Inventor
Rajendiran Chinnapillai
L Ruchelman Alexander
Joseph Connolly Terrence
Venkateswaralu Jasti
Ravikumar Reddy Nallamaddi
Eckert Jeffrey
Joseph Frank Anthony
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47755073&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX350731(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of MX350731B publication Critical patent/MX350731B/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C313/00Sulfinic acids; Sulfenic acids; Halides, esters or anhydrides thereof; Amides of sulfinic or sulfenic acids, i.e. compounds having singly-bound oxygen atoms of sulfinic or sulfenic groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C313/02Sulfinic acids; Derivatives thereof
    • C07C313/06Sulfinamides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C315/00Preparation of sulfones; Preparation of sulfoxides
    • C07C315/04Preparation of sulfones; Preparation of sulfoxides by reactions not involving the formation of sulfone or sulfoxide groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00Sulfones; Sulfoxides
    • C07C317/24Sulfones; Sulfoxides having sulfone or sulfoxide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00Sulfones; Sulfoxides
    • C07C317/26Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C317/28Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to acyclic carbon atoms of the carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05Isotopically modified compounds, e.g. labelled
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07Optical isomers

Abstract

En el presente documento se proveen nuevos procesos para la preparación de intermediarios de aminosultona para la síntesis de 2-[1-(3-etoxi-4-metoxifenil)-2-metilsulfonil-etil]-4-acetilaminoi soindolino-1,3-diona, que es útil para prevenir o tratar enfermedades o condiciones relacionadas con un nivel o actividad anormalmente alto de TNF-a. Además, en el presente documento se proveen procesos para la producción comercial de (S)-1-(3-etoxi-4-metoxifenil)-2-metansulfonil-etilamina.
MX2016016157A 2012-02-21 2013-02-20 Procesos para la preparacion de (s)-1-(3-etoxi-4-metoxifenil)-2-me tansulfoniletilamina. MX350731B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261601226P 2012-02-21 2012-02-21
PCT/US2013/026780 WO2013126360A2 (en) 2012-02-21 2013-02-20 Processes for the preparation of (s)-1-(3-ethoxy-4methoxyphenyl)-2-methanesulfonylethylamine

Publications (1)

Publication Number Publication Date
MX350731B true MX350731B (es) 2017-09-15

Family

ID=47755073

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2014010002A MX344190B (es) 2012-02-21 2013-02-20 Procesos para la preparacion de (s) - 1 - (3 - etoxi - 4 - metoxifenil) - 2 - metansulfoniletilamina.
MX2016016157A MX350731B (es) 2012-02-21 2013-02-20 Procesos para la preparacion de (s)-1-(3-etoxi-4-metoxifenil)-2-me tansulfoniletilamina.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2014010002A MX344190B (es) 2012-02-21 2013-02-20 Procesos para la preparacion de (s) - 1 - (3 - etoxi - 4 - metoxifenil) - 2 - metansulfoniletilamina.

Country Status (36)

Country Link
US (3) US9187417B2 (es)
EP (4) EP3378850B8 (es)
JP (1) JP2015509496A (es)
KR (1) KR101993248B1 (es)
CN (3) CN104245668B (es)
AR (2) AR090100A1 (es)
AU (1) AU2013203283B2 (es)
BR (3) BR122021020040B1 (es)
CA (1) CA2864517A1 (es)
CO (1) CO7061071A2 (es)
CR (1) CR20140395A (es)
CY (2) CY1121833T1 (es)
DK (2) DK3378850T3 (es)
ES (3) ES2675168T3 (es)
HK (1) HK1205501A1 (es)
HR (2) HRP20191249T1 (es)
HU (2) HUE048412T2 (es)
IL (3) IL234135A (es)
IN (1) IN2014DN06740A (es)
LT (2) LT3312156T (es)
MX (2) MX344190B (es)
MY (1) MY168296A (es)
NI (1) NI201400093A (es)
NZ (1) NZ628028A (es)
PH (1) PH12014501865A1 (es)
PL (2) PL3312156T3 (es)
PT (2) PT3312156T (es)
RS (2) RS59071B1 (es)
RU (1) RU2632875C2 (es)
SG (1) SG11201405035XA (es)
SI (2) SI3312156T1 (es)
TR (1) TR201910430T4 (es)
TW (1) TW201336815A (es)
UA (1) UA116773C2 (es)
WO (1) WO2013126360A2 (es)
ZA (1) ZA201405892B (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9126906B2 (en) * 2012-02-21 2015-09-08 Celgene Corporation Asymmetric synthetic processes for the preparation of aminosulfone compounds
AR090100A1 (es) 2012-02-21 2014-10-22 Celgene Corp Procesos para la preparacion de la (s)-1-(3-etoxi-4-metoxifenil)-2-metanosulfoniletilamina
NZ628329A (en) 2013-06-17 2017-12-22 Celgene Corp Formulations of (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
IN2014MU01283A (es) 2014-04-04 2015-10-09 Cadila Healthcare Ltd
WO2015173792A1 (en) 2014-05-11 2015-11-19 Mapi Pharma Ltd. Amorphous form of apremilast
EP2949645A1 (en) 2014-05-28 2015-12-02 LEK Pharmaceuticals d.d. Processes for the preparation of ß-aminosulfone compounds
CN105622380B (zh) * 2014-10-29 2020-06-30 南京安源生物医药科技有限公司 一种阿普斯特的制备方法及其中间体
CN104447445B (zh) * 2014-12-05 2016-07-06 新发药业有限公司 一种合成阿普斯特中间体的制备方法
CN104744323B (zh) * 2015-03-11 2016-08-31 中山奕安泰医药科技有限公司 一种阿普斯特手性胺中间体的合成工艺
CN104761474B (zh) * 2015-03-11 2016-11-30 中山奕安泰医药科技有限公司 一种阿普斯特手性胺中间体的合成方法
CN104803897A (zh) * 2015-04-23 2015-07-29 中山奕安泰医药科技有限公司 一种阿普斯特中间体的合成工艺
US10370329B2 (en) * 2015-04-27 2019-08-06 Mylan Laboratories Limited Process for the enantiomeric resolution of apremilast intermediates
US20180334429A1 (en) * 2015-06-09 2018-11-22 Dr. Reddy's Laboratories Limited Process for preparation of apremilast and its intermediates
EP3106457A1 (en) 2015-06-15 2016-12-21 LEK Pharmaceuticals d.d. A novel synthetic pathway towards apremilast
EP3144393A1 (en) * 2015-09-18 2017-03-22 LEK Pharmaceuticals d.d. A synthetic pathway towards apremilast
WO2017059040A1 (en) 2015-09-29 2017-04-06 Pliva Hrvatska D.O.O. Processes for the preparation of apremilast and intermediates thereof
US10399942B2 (en) 2015-11-19 2019-09-03 Alembic Pharmaceuticals Limited Process and novel polymorphic form of Apremilast
CN105461602B (zh) * 2015-11-27 2018-01-02 东华大学 手性S或R‑3‑乙氧基‑4‑甲氧基‑α‑[(甲磺酰基)甲基]苯甲醇的制备方法
CN105330586B (zh) * 2015-11-27 2017-12-22 东华大学 一种阿普斯特的制备方法
WO2017094031A2 (en) * 2015-12-04 2017-06-08 Sun Pharmaceutical Industries Limited Novel process for preparation of apremilast
CN106866475B (zh) * 2015-12-11 2018-03-30 北大方正集团有限公司 一种阿普斯特中间体及其制备方法
US10774041B2 (en) 2016-04-15 2020-09-15 Davuluri Ramamohan Rao Process for the preparation of apremilast
US10196355B2 (en) 2016-06-20 2019-02-05 Johnson Matthey Public Limited Company Forms of apremilast
CN106543050B (zh) * 2016-09-28 2018-04-10 中南大学湘雅医院 一种阿普斯特中间体的合成工艺
WO2018061034A1 (en) * 2016-09-30 2018-04-05 Sun Pharmaceutical Industries Limited Novel process for the preparation of 1-(3-ethoxy-4-methoxy-phenyl)-2-methylsulfonyl-ethanamine
JP6684968B2 (ja) 2016-11-10 2020-04-22 エス・エム・エス・グループ・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 連続鋳造圧延設備内において、金属的なストリップを製造するための方法
CN107445875A (zh) * 2017-03-22 2017-12-08 陕西科技大学 一种用于制备阿普斯特的高纯度中间体的手性拆分方法
WO2018184933A1 (en) 2017-04-04 2018-10-11 Quimica Sintetica, S. A. Racemic beta-aminosulfone compounds
ES2829253T3 (es) 2017-04-04 2021-05-31 Quim Sintetica S A Resolución de compuestos de beta-aminosulfona racémicos
CN107966509B (zh) * 2017-11-23 2020-06-23 中山奕安泰医药科技有限公司 一种(s)-1-(3-乙氧基-4-甲氧基苯基)-2-(甲基磺酰基)乙胺的检测方法
CN107827722B (zh) * 2017-11-23 2021-02-19 中山奕安泰医药科技有限公司 一种3-乙氧基-4-甲氧基苯甲醛的合成方法
CN108008035B (zh) * 2017-11-23 2020-07-07 中山奕安泰医药科技有限公司 3-乙氧基-4-甲氧基苯甲醛纯度的检测方法
CN107941945B (zh) * 2017-11-23 2020-12-22 中山奕安泰医药科技有限公司 一种3-乙氧基-4-甲氧基苯甲腈的检测方法
CN107976501B (zh) * 2017-11-23 2020-08-25 中山奕安泰医药科技有限公司 一种1-(3-乙氧基-4-甲氧基苯基)-2-(甲基磺酰基)乙胺的检测方法
CN108084066A (zh) * 2017-12-12 2018-05-29 中山大学 一种阿普斯特及对映异构体的合成方法
JP6673614B1 (ja) * 2018-10-16 2020-03-25 東芝エレベータ株式会社 防音装置
CN113896674B (zh) * 2021-09-01 2023-10-27 深圳华中科技大学研究院 一种阿普斯特的合成方法
CN115850129B (zh) * 2023-02-28 2023-05-16 凯莱英生命科学技术(天津)有限公司 (s)-1-(3-乙氧基-4-甲氧基苯基)-2-(甲磺酰基)乙胺的制备方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3878252A (en) * 1970-09-24 1975-04-15 Burroughs Wellcome Co Ring substituted beta-hydroxy-phenyethylmethyl sulphone or sulphoxide
GB1261455A (en) * 1969-03-06 1972-01-26 Burroughs Wellcome Co Improvements in or relating to substituted acrylonitriles
DE2051871A1 (en) * 1969-05-16 1971-11-18 The Wellcome Foundation Ltd., London Beta-amino-alpha-aryloxymethylacrylonitrile - and 2,4-diamino-5-benzylpyrimidine derivs. useful as antibacterial agents
KR20000064735A (ko) 1996-03-22 2000-11-06 미리암 디. 메코너헤이, 블레어큐. 퍼거슨 R-α-프로필-피페로닐 아민 및 그의 유사체의 신규 비대칭 합성 방법
US6020358A (en) * 1998-10-30 2000-02-01 Celgene Corporation Substituted phenethylsulfones and method of reducing TNFα levels
US7893101B2 (en) 2002-03-20 2011-02-22 Celgene Corporation Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
US6962940B2 (en) 2002-03-20 2005-11-08 Celgene Corporation (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
JP5269281B2 (ja) 2002-12-30 2013-08-21 セルジーン コーポレイション フルオロアルコキシ置換1,3−ジヒドロイソインドリル化合物およびそれらの医薬としての使用
US7208526B2 (en) 2005-05-20 2007-04-24 Hoffmann-La Roche Inc. Styrylsulfonamides
CA2711576C (en) * 2008-01-25 2016-06-21 High Point Pharmaceuticals, Llc Tricyclic compounds as inhibitors of tnf-.alpha. synthesis and as pde4 inhibitors
CN102209709B (zh) 2008-09-10 2014-08-13 细胞基因公司 制备氨基砜化合物的方法
RS53357B (en) * 2009-06-18 2014-10-31 Concert Pharmaceuticals Inc. ISOINDOLINE-1,3-DION DEUTERUM DERIVATIVES AS PDE4 AND TNF-ALPHA INHIBITORS
RU2557236C2 (ru) 2009-10-09 2015-07-20 Селджин Корпорейшн Способ получения соединений 2-(1-фенилэтил)изоиндолин-1-она
WO2012097116A2 (en) 2011-01-14 2012-07-19 Celgene Corporation Isotopologues of isoindole derivatives
AR090100A1 (es) * 2012-02-21 2014-10-22 Celgene Corp Procesos para la preparacion de la (s)-1-(3-etoxi-4-metoxifenil)-2-metanosulfoniletilamina
US9126906B2 (en) * 2012-02-21 2015-09-08 Celgene Corporation Asymmetric synthetic processes for the preparation of aminosulfone compounds

Also Published As

Publication number Publication date
PH12014501865B1 (en) 2014-11-17
EP3702347A1 (en) 2020-09-02
JP2015509496A (ja) 2015-03-30
HRP20191249T1 (hr) 2019-10-18
CY1121833T1 (el) 2020-10-14
US9688623B2 (en) 2017-06-27
RS59071B1 (sr) 2019-09-30
ES2675168T3 (es) 2018-07-09
US20160031808A1 (en) 2016-02-04
EP3378850B8 (en) 2020-03-04
US20130217918A1 (en) 2013-08-22
WO2013126360A3 (en) 2013-10-31
HUE048412T2 (hu) 2020-07-28
PT3312156T (pt) 2019-07-19
LT3312156T (lt) 2019-08-12
MX2014010002A (es) 2014-09-08
PT3378850T (pt) 2020-03-06
EP3702347B1 (en) 2023-11-08
DK3378850T3 (da) 2020-03-16
PL3312156T3 (pl) 2019-10-31
EP3312156A1 (en) 2018-04-25
CY1122799T1 (el) 2021-05-05
KR101993248B1 (ko) 2019-06-26
US20170129852A1 (en) 2017-05-11
BR122021020040B1 (pt) 2022-05-31
CN104245668A (zh) 2014-12-24
PL3378850T3 (pl) 2020-07-27
EP2817288B1 (en) 2018-05-30
HUE044192T2 (hu) 2019-10-28
IL252459B (en) 2020-03-31
WO2013126360A2 (en) 2013-08-29
TR201910430T4 (tr) 2019-08-21
BR112014020444A2 (pt) 2020-10-27
TW201336815A (zh) 2013-09-16
MY168296A (en) 2018-10-23
SG11201405035XA (en) 2014-09-26
RU2632875C2 (ru) 2017-10-11
SI3378850T1 (sl) 2020-07-31
UA116773C2 (uk) 2018-05-10
CO7061071A2 (es) 2014-09-19
ES2773686T3 (es) 2020-07-14
US9586897B2 (en) 2017-03-07
BR122021020046B1 (pt) 2022-05-31
NI201400093A (es) 2016-11-30
EP3378850A1 (en) 2018-09-26
ZA201405892B (en) 2015-11-25
HRP20200245T1 (hr) 2020-05-15
US9187417B2 (en) 2015-11-17
KR20140126389A (ko) 2014-10-30
CN112812044B (zh) 2023-05-30
BR112014020444B1 (pt) 2021-12-07
CR20140395A (es) 2014-11-17
AU2013203283A1 (en) 2013-09-05
SI3312156T1 (sl) 2019-09-30
EP3312156B1 (en) 2019-06-05
AR117963A2 (es) 2021-09-08
RS60036B1 (sr) 2020-04-30
PH12014501865A1 (en) 2014-11-17
IL252459A0 (en) 2017-07-31
AR090100A1 (es) 2014-10-22
AU2013203283B2 (en) 2015-11-26
CN112812044A (zh) 2021-05-18
ES2735801T3 (es) 2019-12-20
EP2817288A2 (en) 2014-12-31
NZ628028A (en) 2016-03-31
MX344190B (es) 2016-12-08
IL273050A (en) 2020-04-30
HK1205501A1 (en) 2015-12-18
CA2864517A1 (en) 2013-08-29
DK3312156T3 (da) 2019-07-22
RU2014138037A (ru) 2016-04-10
EP3378850B1 (en) 2020-01-08
IN2014DN06740A (es) 2015-05-22
CN104245668B (zh) 2017-05-17
LT3378850T (lt) 2020-04-10
CN107033042A (zh) 2017-08-11
IL234135A (en) 2017-06-29

Similar Documents

Publication Publication Date Title
MX350731B (es) Procesos para la preparacion de (s)-1-(3-etoxi-4-metoxifenil)-2-me tansulfoniletilamina.
CY1122795T1 (el) Ινδαζολο-3-καρβοξαμιδια και η χρηση τους ως αναστολεις του σηματοδοτικου μονοπατιου wnt/b-κατενινης
MX2013009068A (es) Compuestos y metodos para la modulacion de quinasas e indicaciones para los mismos.
MX2012003770A (es) Metodos para la modulacion de autofagia a traves de la modulacion de productos de genes que aumentan la autofagia.
EA201891833A1 (ru) Комбинация для лечения амиотрофического бокового склероза или родственных болезней
MY186267A (en) Kinase inhibitor polymorphs
PH12014502513A1 (en) Nampt inhibitors
NZ711896A (en) Compounds and methods for kinase modulation, and indications therefor
MX2014013752A (es) Inhibidores de nampt.
EA026892B9 (ru) ТРИАЗОЛОНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ mPGES-1
EA201290644A1 (ru) Блокаторы натриевых потенциал-зависимых каналов
UA113750C2 (xx) Склад (+)-2-$1-(3-етокси-4-метоксифеніл)-2-метансульфонілетил]-4-ацетиламіноізоіндолін-1,3-діону
MX348311B (es) Inhibidores nampt.
AU2011286276A8 (en) Substituted Biphenylene Compounds and methods of use thereof for the treatment of viral diseases
EA201490423A1 (ru) СПОСОБЫ И КОМПОЗИЦИИ, ОТНОСЯЩИЕСЯ К p62, ДЛЯ ЛЕЧЕНИЯ И ПРОФИЛАКТИКИ РАКА
MX2013012652A (es) Derivados de n-[(1h-pirazol-1-il)aril]-1h-indol o 1h-indazol-3-carboxamida, su preparacion y su uso como antagonistas p2y12.
MX2013001906A (es) Metodos para reducir la concentracion de lactato en la sangre.
CU20160083A7 (es) Un proceso para preparar el compuesto (r)-1-((s)-2,2-dimetil-1,3-dioxolan-4-il)etanol y sus productos intermediarios
MX2014013758A (es) Derivados de tiazolcarboxamida para usarse como inhibidores de nampt.
CR11631A (es) Paramyxovirus eficaz como antitumoral
EA201492169A1 (ru) Новые соединения
EA201001362A1 (ru) Хинолины в качестве ингибиторов фарнезилпирофосфатсинтазы
EA033160B1 (ru) Соединения для лечения заболеваний, связанных с ишемией-реперфузией
MX2014004853A (es) 1-cicloalquil- o 1-heterociclil-hidroxiimino-3-fenil-propanos.
AR118704A2 (es) Polipéptido del factor vii para tratar enfermedades